Clinical Trials

Phase 2/3 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

363 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05221645 2026-05-15

P+R-ICE

65 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03321643 2026-05-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

24 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

422 enrolled

Phase NA Active not recruiting

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT01829958 2026-05-06

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

201 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04978584 2026-05-05

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04546620 2026-04-30

REMoDL-A

453 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04384484 2026-04-28

LOTIS 5

440 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05798156 2026-04-08

R-Pola-Glo

125 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

27 enrolled 11 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT01959698 2026-01-28

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

29 enrolled 19 charts

Lymphoma, Large B-Cell, Diffuse

NCT04833114 2025-09-30

Pola-R-ICE

306 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04479267 2025-09-29

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

8 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04665765 2025-09-03

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

41 enrolled 12 charts

Lymphoma, Large B-Cell, Diffuse

NCT02734771 2025-08-12

BV mini CHP

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

51 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06601504 2025-06-06

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

61 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04460248 2025-05-02

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

40 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05578976 2025-01-23

EPCORE DLBCL-2

900 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04914741 2024-08-12

COALITION

80 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02628405 2024-07-01

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

30 enrolled 15 charts